1. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany
- Author
-
Folgerdiena M. de Vries, Marcel A. Müller, N. Ahmad Aziz, Antonio Schmandke, Marie Luisa Schmidt, Thomas H. Schmidt, Monique M.B. Breteler, Christian Drosten, Anja Richter, Antje K.C. Echterhoff, and Victor M. Corman
- Subjects
0301 basic medicine ,Male ,Epidemiology ,virology [COVID-19] ,General Physics and Astronomy ,Antibodies, Viral ,Immunoglobulin G ,Cohort Studies ,0302 clinical medicine ,Applied immunology ,Seroepidemiologic Studies ,Germany ,immunology [SARS-CoV-2] ,030212 general & internal medicine ,Aged, 80 and over ,Immunoassay ,Multidisciplinary ,medicine.diagnostic_test ,biology ,methods [Immunoassay] ,Middle Aged ,Population Surveillance ,Female ,ddc:500 ,methods [Population Surveillance] ,Antibody ,Cohort study ,Adult ,immunology [Immunoglobulin G] ,Science ,prevention & control [COVID-19] ,Immunofluorescence ,General Biochemistry, Genetics and Molecular Biology ,Article ,immunology [Antibodies, Viral] ,03 medical and health sciences ,Plaque reduction neutralization test ,Neutralization Tests ,methods [Neutralization Tests] ,medicine ,Seroprevalence ,Humans ,physiology [SARS-CoV-2] ,Aged ,business.industry ,SARS-CoV-2 ,COVID-19 ,General Chemistry ,diagnosis [COVID-19] ,Virology ,Antibodies, Neutralizing ,immunology [Antibodies, Neutralizing] ,030104 developmental biology ,Viral infection ,biology.protein ,business - Abstract
To estimate the seroprevalence and temporal course of SARS-CoV-2 neutralizing antibodies, we embedded a multi-tiered seroprevalence survey within an ongoing community-based cohort study in Bonn, Germany. We first assessed anti-SARS-CoV-2 immunoglobulin G levels with an immunoassay, followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (PRNT). Those with a borderline or positive immunoassay result were retested after 4 to 5 months. At baseline, 4771 persons participated (88% response rate). Between April 24th and June 30th, 2020, seroprevalence was 0.97% (95% CI: 0.72−1.30) by immunoassay and 0.36% (95% CI: 0.21−0.61) when considering only those with two additional positive confirmatory tests. Importantly, about 20% of PRNT+ individuals lost their neutralizing antibodies within five months. Here, we show that neutralizing antibodies are detectable in only one third of those with a positive immunoassay result, and wane relatively quickly., Population-based studies of SARS-CoV-2 seroprevalence are needed to understand levels of immunity and antibody dynamics. Here, the authors show that the seroprevalence in Bonn, Germany was low (
- Published
- 2020
- Full Text
- View/download PDF